Press release & events

NEW IN VIVO SHUTTLE CAMPAIGN!

09 / 08 / 2022

NEW IN VIVO SHUTTLE CAMPAIGN!

Save the date for our new in vivo shuttle campaign!

We are committed to providing world-class supports to advance your preclinical projects and immunotherapy drug discovery using syngeneic tumor mouse models through our comprehensive in vivo Immuno-Oncology platform.

Sign up! It’s for early November

Image of the month - July

07 / 12 / 2022

Image of the month - July

Check out - it's our favorite image of the month

What a pretty multiplexed image showing the tumor microenvironment (TME) on a human NSCLC section, highlighting PDL1 positive tumor cells surrounded by macrophages and T cells.

 

Gearing up for ASCO 2022 event! Meet Explicyte in Chicago!

05 / 19 / 2022

Gearing up for ASCO 2022 event! Meet Explicyte in Chicago!

From June 3 to 7, 2022, we will be setting up our quarters in Chicago for the American Society of Clinical Oncology Annual Meeting to continue gaining the latest insights in research and clinical development in Oncology. Also, our CEO Dr. Alban Bessede will have the great opportunity to present a scientific poster highlighting our recent advances in biomarker research in Immuno-Oncology.

It’s time to download our posters presented at AACR 2022!

04 / 21 / 2022

It’s time to download our posters presented at AACR 2022!

Back from the AACR 2022, it was a pleasure to take part in it and to converse about our posters showcasing our newest preclinical and translational research advances in Immuno-Oncology.

If you didn't get the chance to meet us and see our posters, or if you want to review them, you can directly download them from the form below.

We'll be there! Meet Explicyte at AACR event in New Orleans

03 / 29 / 2022

We'll be there! Meet Explicyte at AACR event in New Orleans

We will be attending the AACR Annual Meeting in New Orleans, from April 8 to 13, 2022. We will be glad to take this opportunity to meet you there,  approach your research projects and introduce our service offerings. We will also presentsome scientific posters to highlight our latest innovative preclinical and translational research advances.

Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology

03 / 10 / 2022

Domain Therapeutics and Explicyte enter  partnership agreement in immuno-oncology

Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), and Explicyte, an expert in the field of IO and innovative target identification through multiparametric approaches, announce today the signing of a partnership agreement. The two companies will combine their expertise to identify GPCR targets and associated biomarkers to discover and develop breakthrough therapeutic programs for IO. Financial terms are not disclosed.

CONDOR project for precision medicine and sarcoma immunotherapy awarded close to €10M in the fifth RHU call

01 / 27 / 2022

CONDOR project for precision medicine and sarcoma immunotherapy awarded close to €10M in the fifth RHU call

January 27, 2022 – The CONDOR consortium, led by Pr. Antoine Italiano of the Bergonié Institute (Bordeaux, France) is one of the 17 national awardees in the fifth call for projects in Hospital-University Research in Health (RHU5), selected from the 89 applications submitted. This €30M ($34M) project will benefit from a grant of more than €9.8M ($11.1M) to implement a multi-modal project combining precision medicine and immunotherapies for the management of patients with Soft Tissue Sarcomas (STS).